Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.
Wei-Fan HsuHsueh-Chou LaiWen-Pang SuChia-Hsin LinPo-Heng ChuangSheng-Hung ChenHung-Yao ChenHung-Wei WangGuan-Tarn HuangCheng-Yuan PengPublished in: BMC gastroenterology (2019)
Noninvasive fibrosis indices, namely APRI and FIB-4, exhibited a rapid and sustained decline from week 2 until PW12 in patients with CHC who achieved SVR to DAA therapy. The rapid decline in APRI and FIB-4 values might mainly result from improvement in necroinflammation.